BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2515811)

  • 1. LH-RH agonist (buserelin): treatment of endometriosis. Clinical, laparoscopic, endocrine and metabolic evaluation.
    Cirkel U; Schweppe KW; Ochs H; Hanker JP; Schneider HP
    Arch Gynecol Obstet; 1989; 246(3):139-51. PubMed ID: 2515811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversible hypogonadism induced by a luteinizing hormone-releasing hormone (LH-RH) agonist (Buserelin) as a new therapeutic approach for endometriosis.
    Lemay A; Maheux R; Faure N; Jean C; Fazekas AT
    Fertil Steril; 1984 Jun; 41(6):863-71. PubMed ID: 6427019
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible pituitary ovarian suppression induced by an LHRH agonist in the treatment of endometriosis--comparison of two dose regimens.
    Shaw RW; Matta W
    Clin Reprod Fertil; 1986 Oct; 4(5):329-36. PubMed ID: 3100012
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Inhibitory effect of prolactin secretion by luteinizing hormone releasing hormone agonist (buserelin)].
    Inoue T; Matsuoka R; Mori H; Kigawa T
    Nihon Naibunpi Gakkai Zasshi; 1986 Jun; 62(6):745-53. PubMed ID: 3093292
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of LHRH agonist (buserelin) on pulsatile secretion of LHRH and LH.
    Okuda K; Ushiroyama T; Yoshikawa M; Sugimoto O
    Nihon Sanka Fujinka Gakkai Zasshi; 1988 Dec; 40(12):1889-93. PubMed ID: 3145318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential new treatment of endometriosis: reversible inhibition of pituitary-ovarian function by chronic intranasal administration of a luteinizing hormone-releasing hormone (LH-RH) agonist.
    Lemay A; Quesnel G
    Fertil Steril; 1982 Sep; 38(3):376-9. PubMed ID: 6214431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Androgens and other hormones in buserelin therapy].
    Fuchs U; Zwirner M
    Geburtshilfe Frauenheilkd; 1991 Feb; 51(2):140-2. PubMed ID: 1904040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contraception with an LHRH agonist: effect on gonadotrophin and steroid secretion patterns.
    Kuhl H; Jung C; Taubert HD
    Clin Endocrinol (Oxf); 1984 Aug; 21(2):179-88. PubMed ID: 6432376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Buserelin versus danazol in the treatment of endometriosis-associated infertility.
    Fedele L; Bianchi S; Arcaini L; Vercellini P; Candiani GB
    Am J Obstet Gynecol; 1989 Oct; 161(4):871-6. PubMed ID: 2529770
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
    Biberoglu K; Gursoy R; Yildiz A
    Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of endometriosis with gonadotropin releasing hormone agonist (buserelin).
    Sirimongkolkasem R; Rojanasakul A; Chailurkit LO
    J Med Assoc Thai; 1990 Feb; 73 Suppl 1():37-41. PubMed ID: 2112582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endometriosis: treatment with gonadotropin-releasing hormone agonist Buserelin.
    Franssen AM; Kauer FM; Chadha DR; Zijlstra JA; Rolland R
    Fertil Steril; 1989 Mar; 51(3):401-8. PubMed ID: 2522063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ovarian suppression induced with Buserelin or danazol in the management of endometriosis: a randomized, comparative study.
    Dmowski WP; Radwanska E; Binor Z; Tummon I; Pepping P
    Fertil Steril; 1989 Mar; 51(3):395-400. PubMed ID: 2493400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
    Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
    Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
    Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
    J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of LH and FSH secretion by LH-releasing hormone, by the LH-releasing hormone analogue, buserelin, and by combined treatment with LH-releasing hormone and oestradiol benzoate.
    Schuiling GA; Pols-Valkhof N; van der Schaaf-Verdonk GC; Koiter TR
    J Endocrinol; 1984 Dec; 103(3):301-9. PubMed ID: 6438265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of endometriosis with goserelin depot, a long-acting gonadotropin-releasing hormone agonist analog: endocrine and clinical results.
    Venturini PL; Fasce V; Costantini S; Anserini P; Cucuccio S; de Cecco L
    Fertil Steril; 1990 Dec; 54(6):1021-7. PubMed ID: 2147154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fourteen-day versus twenty-one-day regimens of intermittent intranasal luteinizing hormone-releasing hormone agonist combined with an oral progestogen as antiovulatory contraceptive approach.
    Lemay A; Faure N
    J Clin Endocrinol Metab; 1986 Dec; 63(6):1379-85. PubMed ID: 2946711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful treatment of endometriosis in women with continuous subcutaneous infusion of gonadotropin-releasing hormone agonist (GnRH-A)].
    Masaoka K; Kitazawa M; Kumasaka T
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Apr; 41(4):405-11. PubMed ID: 2501437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term suppression of ovarian function by a luteinizing-hormone releasing hormone agonist implant in patients with endometriosis.
    Fraser HM; Sandow J; Cowen GM; Lumsden MA; Haining R; Smith SK
    Fertil Steril; 1990 Jan; 53(1):61-8. PubMed ID: 2104808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.